

Supplementary Information

Diversity-oriented synthesis of pyrazolo[4,3-*b*]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors

Zengye Hou,^a Shinya Oishi,^a Yamato Suzuki,^a Tatsuhide Kure,^b Isao Nakanishi,^b Akira Hirasawa,^a
Gozoh Tsujimoto,^a Hiroaki Ohno*^a and Nobutaka Fujii*^a

^a Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

Tel: +81-75-753-4551; Fax: +81-75-753-4570

E-mail: hohno@pharm.kyoto-u.ac.jp; nfujii@pharm.kyoto-u.ac.jp


^b Faculty of Pharmacy, Kinki University, 3-4-1 Kowakae, Higashi-osaka 577-8502, Japan

Table of contents


Experimental section	S2
NMR spectra	S22

Experimental section


Synthesis of aryl azides **6a–c** and **12**




Compounds **S1a**,¹ **S1b**,² **S1c**,³ and **S2**⁴ were prepared according to the literature.




Representative procedure: synthesis of ethyl 3-azido-4-ethynylbenzoate (6b). To a solution of **S1b** (1286 mg, 6.8 mmol) in MeCN (24 mL), DMF (4 mL) and 10% aqueous H₂SO₄ (8 mL) was added dropwise a solution of NaNO₂ (563 mg, 8.2 mmol) in H₂O (2 mL) at 0 °C. The reaction mixture was stirred at the same temperature for 30 min. Then, a solution of NaN₃ (530 mg, 8.2 mmol) in H₂O (2 mL) was added dropwise to the mixture at 0 °C. The mixture was allowed to warm to room temperature and stirred for further 30 min. The resulting mixture was diluted with H₂O and extracted with EtOAc twice. The combined extracts were washed with brine, dried over Na₂SO₄, and concentrated in vacuo. The residue was chromatographed on silica gel (hexane/EtOAc = 8/1) followed by recrystallization from EtOAc–hexane to afford the title compound **6b** (1.20 g, 82%) as light yellow crystals: mp 75 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 3236 (C≡CH), 2111 (N₃), 1699 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.41 (t, *J* = 7.2 Hz, 3H), 3.53 (s, 1H), 4.40 (q, *J* = 7.2 Hz, 2H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.76 (d, *J* = 8.0 Hz, 1H), 7.80 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.2, 61.6, 78.7, 85.4, 118.1, 119.4, 125.4, 132.0, 134.2, 142.1, 165.1; HRMS (FAB⁺) calcd for C₁₁H₁₀N₃O₂ [*M*+H]⁺: 216.0773, found: 216.0765.




1-Azido-2-ethynylbenzene (6a). By use of the procedure for the synthesis of **6b**, **S1a** (1.02 g, 8.7 mmol) was converted to the title compound **6a** (1.02 mg, 82%) as a yellow oil: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 3295 (C≡CH), 2106 (N₃); ¹H-NMR (500 MHz, CDCl₃) δ : 3.38 (s, 1H), 7.08–7.15 (m, 2H), 7.36–7.39 (m, 1H), 7.47–7.49 (m, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 79.3, 82.9, 114.1, 118.5, 124.6, 130.1, 134.3, 141.7; HRMS (FAB⁺) calcd for C₈H₆N₃ [*M*+H]⁺: 144.0562, found: 144.0553.




2-Azido-1-ethynyl-4-methoxybenzene (6c). By use of the procedure for the synthesis of **6b**, **S1c** (900 mg, 6.1 mmol) was converted to the title compound **6c** (656 mg, 62%) as yellow crystals: mp 52 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 3281 (C≡CH), 2114 (N₃); ¹H-NMR (500 MHz, CDCl₃) δ : 3.30 (s, 1H), 3.82 (s, 3H), 6.61–6.64 (m, 2H), 7.38 (d, *J* = 8.0 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 55.5, 79.3, 81.3, 104.3, 106.5, 110.7, 135.2, 142.9, 161.0; HRMS (FAB⁺) calcd for C₉H₈N₃O [*M*+H]⁺: 174.0667, found: 174.0659.



Ethyl 3-azido-4-iodobenzoate (12). By use of the procedure for the synthesis of **6b**, **S2** (3.30 g, 11.3 mmol) was converted to the title compound **12** (2.48 g, 69%) as colourless crystals: mp 43 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 2110 (N₃), 1706 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.41 (t, *J* = 7.2 Hz, 3H), 4.40 (q, *J* = 7.2 Hz, 2H), 7.48–7.51 (m, 1H), 7.76–7.77 (m, 1H), 7.87 (d, *J* = 8.0 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 61.6, 93.8, 118.8, 126.8, 132.1, 140.2, 142.3, 165.3; HRMS (FAB⁺) calcd for C₉H₉IN₃O₂ [*M*+H]⁺: 317.9740, found: 317.9746.




Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-3-isopropyl-2-(4-methoxybenzyl)-2,3-dihydro-1H-pyrazole-1-carboxylate (9b). By use of the procedure for the synthesis of **9a**, **6b** (108 mg, 0.5 mmol), hydrazine **8a** (158 mg, 0.75 mmol) and isobutyraldehyde (68 μL , 0.75 mmol) were converted to the title compound **9b** (230 mg, 96%) as a yellow oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2116 (N_3), 1710 ($\text{C}=\text{O}$); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ : 0.75–0.77 (m, 6H), 1.40 (t, $J = 6.9$ Hz, 3H), 1.52–1.58 (m, 1H), 3.38 (dd, $J = 6.0, 2.9$ Hz, 1H), 3.59 (s, 3H), 3.77 (d, $J = 12.0$ Hz, 1H), 3.81 (s, 3H), 4.08 (d, $J = 12.0$ Hz, 1H), 4.38–4.43 (m, 2H), 5.54 (d, $J = 2.9$ Hz, 1H), 6.87 (d, $J = 8.6$ Hz, 2H), 7.37–7.39 (m, 3H), 7.77–7.79 (m, 1H), 7.85 (s, 1H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ : 14.3, 18.1, 18.2, 32.8, 52.7, 55.2, 61.3, 61.7, 73.9, 113.3 (2C), 114.5, 119.4, 125.4, 128.5, 128.8, 130.1, 131.3, 131.5 (2C), 136.6, 138.1, 155.2, 159.1, 165.5; HRMS (FAB $^+$) calcd for $\text{C}_{25}\text{H}_{30}\text{N}_5\text{O}_5$ [$M+\text{H}$] $^+$: 480.2247, found: 480.2250.




Methyl 5-(2-azido-4-methoxyphenyl)-3-isopropyl-2-(4-methoxybenzyl)-2,3-dihydro-1H-pyrazole-1-carboxylate (9c). By use of the procedure for the synthesis of **9a**, **6c** (43 mg, 0.25 mmol), hydrazine **8a** (79 mg, 0.38 mmol) and isobutyraldehyde (34 μL , 0.38 mmol) were converted to the title compound **9c** (100 mg, 91%) as a yellow oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2109 (N_3), 1712 ($\text{C}=\text{O}$); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ : 0.74–0.76 (m, 6H), 1.49–1.55 (m, 1H), 3.32 (dd, $J = 5.7, 2.9$ Hz, 1H), 3.60 (s, 3H), 3.76 (d, $J = 12.0$ Hz, 1H), 3.81 (s, 3H), 3.83 (s, 3H), 4.06 (d, $J = 12.0$ Hz, 1H), 5.35 (d, $J = 2.9$ Hz, 1H), 6.65–6.70 (m, 2H), 6.86 (d, $J = 8.6$ Hz, 2H), 7.23 (d, $J = 8.6$ Hz, 1H), 7.37 (d, $J = 8.6$ Hz, 2H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ : 18.0, 18.2, 32.8, 52.5, 55.2, 55.4, 61.6, 73.5, 104.3,

109.9, 111.8, 113.3 (2C), 117.5, 129.1, 131.2, 131.5 (2C), 137.0, 138.8, 155.0, 159.0, 160.4; HRMS (FAB⁺) calcd for C₂₃H₂₈N₅O₄ [M+H]⁺: 438.2142, found: 438.2134.




tert-Butyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-benzyl-3-isopropyl-2,3-dihydro-1H-pyrazole-1-carboxylate (9d). By use of the procedure for the synthesis of **9a**, **6b** (54 mg, 0.25 mmol), hydrazine **8b** (83 mg, 0.38 mmol) and isobutyraldehyde (34 μ L, 0.38 mmol) were converted to the title compound **9d** (98 mg, 80%) as a yellow oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2114 (N₃), 1712 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 0.75–0.78 (m, 6H), 1.24 (s, 9H), 1.41 (t, J = 6.9 Hz, 3H), 1.50–1.56 (m, 1H), 3.31 (dd, J = 5.7, 2.9 Hz, 1H), 3.79 (d, J = 12.0 Hz, 1H), 4.16 (d, J = 12.0 Hz, 1H), 4.40 (q, J = 6.9 Hz, 2H), 5.52 (d, J = 2.9 Hz, 1H), 7.26–7.29 (m, 1H), 7.31–7.34 (m, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.47–7.49 (m, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.84 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 18.08, 18.10, 27.9 (3C), 32.7, 61.3, 62.3, 73.8, 80.6, 114.1, 119.5, 125.3, 127.3, 127.9 (2C), 129.6, 130.0, 130.4 (2C), 131.0, 136.85, 136.94, 137.9, 153.3, 165.5; HRMS (FAB⁺) calcd for C₂₇H₃₄N₅O₄ [M+H]⁺: 492.2611, found: 492.2609.




Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-(4-methoxybenzyl)-3-propyl-2,3-dihydro-1H-pyrazole-1-carboxylate (9e). By use of the procedure for the synthesis of **9a**, **6b** (54 mg, 0.25 mmol), hydrazine **8a** (79 mg, 0.38 mmol) and *n*-butyraldehyde (34 μ L, 0.38 mmol) were converted to the title compound **9e** (94 mg, 78%) as a yellow oil. In this case, AgNTf₂ (2.9 mg, 0.0075 mmol) was used instead of AgOTf: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2112 (N₃), 1713 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 0.77 (t, J = 7.2 Hz, 3H), 1.10–1.34 (m, 4H), 1.40 (t, J = 7.2 Hz, 3H), 3.57–3.60 (m, 4H), 3.78–3.81 (m, 4H), 4.09 (d, J = 12.0 Hz, 1H), 4.38–4.42 (m, 2H), 5.59 (d, J = 2.9 Hz, 1H), 6.87 (d, J

= 8.6 Hz, 2H), 7.37–7.39 (m, 3H), 7.77–7.79 (m, 1H), 7.85 (s, 1H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 13.8, 14.3, 18.5, 37.0, 52.7, 55.2, 60.9, 61.3, 67.8, 113.4 (2C), 116.5, 119.4, 125.4, 128.7, 128.8, 130.1, 131.2 (2C), 131.3, 136.0, 138.0, 155.2, 159.0, 165.4; HRMS (FAB^+) calcd for $\text{C}_{25}\text{H}_{30}\text{N}_5\text{O}_5$ [$M+\text{H}$] $^+$: 480.2247, found: 480.2241.




Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-3-benzyl-2-(4-methoxybenzyl)-2,3-dihydro-1H-pyrazole-1-carboxylate (9f). By use of the procedure for the synthesis of **9a**, **6b** (54 mg, 0.25 mmol), hydrazine **8a** (79 mg, 0.38 mmol) and 2-phenylacetaldehyde (49 μL , 0.38 mmol) were converted to the title compound **9f** (67 mg, 51%) as a yellow oil. In this case, AgNTf_2 (2.9 mg, 0.0075 mmol) was used instead of AgOTf : IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 2114 (N_3), 1714 ($\text{C}=\text{O}$); ^1H -NMR (500 MHz, CDCl_3) δ : 1.39 (t, $J = 7.2$ Hz, 3H), 2.61–2.70 (m, 2H), 3.58 (s, 3H), 3.77 (d, $J = 12.0$ Hz, 1H), 3.79–3.82 (m, 4H), 4.09 (d, $J = 12.0$ Hz, 1H), 4.37–4.42 (m, 2H), 5.49 (d, $J = 2.9$ Hz, 1H), 6.81 (d, $J = 8.6$ Hz, 2H), 7.13–7.14 (m, 2H), 7.17–7.19 (m, 1H), 7.21–7.25 (m, 2H), 7.28–7.31 (m, 3H), 7.75–7.77 (m, 1H), 7.83 (s, 1H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 14.3, 41.5, 52.7, 55.2, 60.8, 61.3, 69.1, 113.5 (2C), 115.2, 119.4, 125.4, 126.2, 127.9 (2C), 128.50, 128.52, 129.7 (2C), 130.2, 130.9 (2C), 131.4, 136.9, 137.5, 138.1, 154.9, 158.9, 165.4; HRMS (FAB^+) calcd for $\text{C}_{29}\text{H}_{30}\text{N}_5\text{O}_5$ [$M+\text{H}$] $^+$: 528.2247, found: 528.2250.




Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-(4-methoxybenzyl)-3-phenyl-2,3-dihydro-1H-pyrazole-1-carboxylate (9g). By use of the procedure for the synthesis of **9a**, **6b** (108 mg, 0.5 mmol), hydrazine **8a** (158 mg, 0.75 mmol) and benzaldehyde (76 μL , 0.75 mmol) were converted to


the title compound **9g** (134 mg, 52%) as a yellow oil. In this case, the reaction was carried out at room temperature using AgNTf₂ (5.8 mg, 0.015 mmol) instead of AgOTf: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 2114 (N₃), 1714 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.40 (t, J = 7.2 Hz, 3H), 3.59 (s, 3H), 3.81 (s, 3H), 4.02 (d, J = 12.0 Hz, 1H), 4.30 (d, J = 12.0 Hz, 1H), 4.37–4.44 (m, 2H), 4.70 (d, J = 3.4 Hz, 1H), 5.73 (d, J = 3.4 Hz, 1H), 6.87 (d, J = 8.0 Hz, 2H), 7.14–7.15 (m, 2H), 7.20–7.28 (m, 3H), 7.41–7.43 (m, 3H), 7.78–7.80 (m, 1H), 7.87 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 52.9, 55.2, 61.4, 61.5, 70.4, 113.6 (2C), 114.8, 119.4, 125.4, 126.7 (2C), 127.4, 128.2, 128.4, 128.6 (2C), 130.3, 131.2 (2C), 131.6, 136.8, 138.3, 140.4, 154.9, 159.2, 165.4; HRMS (FAB⁺) calcd for C₂₈H₂₈N₅O₅ [$M+H$]⁺: 514.2091, found: 514.2089.



Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-(4-methoxybenzyl)-3-(4-nitrophenyl)-2,3-dihydro-1H-pyrazole-1-carboxylate (9h). By use of the procedure for the synthesis of **9a**, **6b** (54 mg, 0.25 mmol), hydrazine **8a** (79 mg, 0.38 mmol) and 4-nitrobenzaldehyde (57 mg, 0.38 mmol) were converted to the title compound **9h** (82 mg, 59%) as a yellow oil. In this case, AgNTf₂ (2.9 mg, 0.0075 mmol) was used instead of AgOTf: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 2115 (N₃), 1714 (C=O), 1514, 1346 (NO₂); ¹H-NMR (500 MHz, CDCl₃) δ : 1.41 (t, J = 6.9 Hz, 3H), 3.63 (s, 3H), 3.81 (s, 3H), 4.02 (d, J = 12.0 Hz, 1H), 4.36 (d, J = 12.0 Hz, 1H), 4.39–4.44 (m, 2H), 4.78 (d, J = 2.9 Hz, 1H), 5.73 (d, J = 2.9 Hz, 1H), 6.88 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 9.2 Hz, 2H), 7.39–7.42 (m, 3H), 7.79–7.81 (m, 1H), 7.88 (s, 1H), 8.13 (d, J = 8.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 53.1, 55.2, 61.3, 61.5, 69.2, 112.8, 113.8 (2C), 119.4, 123.9 (2C), 125.4, 127.4 (2C), 127.5, 127.8, 130.2, 131.1 (2C), 132.0, 137.8, 138.4, 147.3, 147.8, 154.5, 159.4, 165.3; HRMS (FAB⁺) calcd for C₂₈H₂₇N₆O₇ [$M+H$]⁺: 559.1941, found: 559.1939.




Methyl 5-[2-azido-4-(ethoxycarbonyl)phenyl]-2-(4-methoxybenzyl)-3-(4-methoxyphenyl)-2,3-dihydro-1H-pyrazole-1-carboxylate (9i). By use of the procedure for the synthesis of **9a**, **6b** (54 mg, 0.25 mmol), hydrazine **8a** (79 mg, 0.38 mmol) and *p*-anisaldehyde (46 μ L, 0.38 mmol) were converted to the title compound **9i** (42 mg, 31%) as a yellow oil. In this case, AgNTf₂ (2.9 mg, 0.0075 mmol) was used instead of AgOTf: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 2116 (N₃), 1716 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.41 (t, *J* = 7.2 Hz, 3H), 3.58 (s, 3H), 3.76 (s, 3H), 3.82 (s, 3H), 3.99 (d, *J* = 12.0 Hz, 1H), 4.28 (d, *J* = 12.0 Hz, 1H), 4.38–4.45 (m, 2H), 4.65 (d, *J* = 2.9 Hz, 1H), 5.71 (d, *J* = 2.9 Hz, 1H), 6.80 (d, *J* = 9.2 Hz, 2H), 6.88 (d, *J* = 8.6 Hz, 2H), 7.03 (d, *J* = 9.2 Hz, 2H), 7.40–7.45 (m, 3H), 7.79–7.81 (m, 1H), 7.88 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 52.9, 55.2, 55.2, 61.4, 61.5, 70.0, 113.6 (2C), 114.0 (2C), 115.1, 119.4, 125.4, 128.0 (2C), 128.3, 128.5, 130.2, 131.2 (2C), 131.6, 132.5, 136.6, 138.3, 155.0, 159.0, 159.1, 165.4; HRMS (FAB⁺) calcd for C₂₉H₃₀N₅O₆ [*M*+H]⁺: 544.2196, found: 544.2194.




Methyl 3-[2-azido-4-(ethoxycarbonyl)phenyl]-1-(4-methoxybenzyl)-1,2-diazaspiro[4.5]dec-3-ene-2-carboxylate (9j). By use of the procedure for the synthesis of **9a**, **6b** (54 mg, 0.25 mmol), hydrazine **8a** (79 mg, 0.38 mmol) and cyclohexanone (39 μ L, 0.38 mmol) were converted to the title compound **9j** (104 mg, 82%) as a yellow oil. In this case, AgNTf₂ (2.9 mg, 0.0075 mmol) was used instead of AgOTf: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 2115 (N₃), 1715; (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.39 (t, *J* = 7.2 Hz, 3H), 1.48–1.77 (m, 10H), 3.37 (s, 3H), 3.81–3.82 (m, 5H), 4.39 (q, *J* = 7.2 Hz, 2H), 6.07 (s, 1H), 6.86 (d, *J* = 8.6 Hz, 2H), 7.32–7.33 (m, 1H), 7.39 (d, *J* = 8.6 Hz, 2H), 7.75–7.77 (m,

1H), 7.84 (s, 1H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 14.3, 23.4 (2C), 25.6, 33.9 (2C), 52.5, 54.0, 55.2, 61.3, 72.2, 113.0 (2C), 119.6, 123.6, 125.3, 128.6, 130.2, 130.3, 131.0, 131.1 (2C), 136.1, 137.6, 156.6, 158.7, 165.4; HRMS (FAB $^+$) calcd for $\text{C}_{27}\text{H}_{32}\text{N}_5\text{O}_5$ [$M+\text{H}$] $^+$: 506.2403, found: 506.2409.




6-Ethyl 1-methyl 3-isopropyl-2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (10b). By use of the procedure for the synthesis of **10a**, **9b** (210 mg, 0.44 mmol) was converted to the title compound **10b** (170 mg, 85%) as a colourless oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1707; (C=O); ^1H -NMR (500 MHz, CDCl_3) δ : 0.71–0.77 (m, 6H), 1.41 (t, $J = 7.2$ Hz, 3H), 1.71–1.77 (m, 1H), 3.79–3.86 (m, 5H), 3.89 (s, 3H), 4.22 (d, $J = 12.0$ Hz, 1H), 4.40 (q, $J = 7.2$ Hz, 2H), 6.84 (d, $J = 8.6$ Hz, 2H), 7.34 (d, $J = 8.6$ Hz, 2H), 7.82–7.84 (m, 2H), 8.09–8.10 (m, 1H), 8.17 (s, 1H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 14.4, 17.8, 18.4, 33.2, 53.0, 55.2, 60.8, 62.5, 69.8, 113.5 (2C), 114.2, 119.1, 120.0, 121.3, 123.6, 128.4, 131.4 (2C), 133.7, 139.4, 140.6, 151.8, 159.2, 167.6; HRMS (FAB $^+$) calcd for $\text{C}_{25}\text{H}_{30}\text{N}_3\text{O}_5$ [$M+\text{H}$] $^+$: 452.2185, found: 452.2179.



Methyl 3-isopropyl-6-methoxy-2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1-carboxylate (10c). By use of the procedure for the synthesis of **10a**, **9c** (100 mg, 0.23 mmol) was converted to the title compound **10c** (67 mg, 72%) as a yellow oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1698 (C=O); ^1H -NMR (500 MHz, CDCl_3) δ : 0.68–0.73 (m, 6H), 1.65–1.71 (m, 1H), 3.78–3.86 (m, 11H), 4.21 (d, $J = 12.0$ Hz, 1H), 6.80–6.84 (m, 4H), 7.34 (d, $J = 8.6$ Hz, 2H), 7.70–7.78 (m, 2H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 17.7, 18.3, 33.2, 52.9, 55.1, 55.8, 62.4, 70.0, 95.7, 110.0, 111.9, 113.3 (2C), 120.2,

123.6, 128.0, 128.8, 131.3 (2C), 140.9, 154.3, 156.2, 159.1; HRMS (FAB⁺) calcd for C₂₃H₂₈N₃O₄ [M+H]⁺: 410.2080, found: 410.2078.



1-tert-Butyl 6-ethyl 2-benzyl-3-isopropyl-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-

dicarboxylate (10d). By use of the procedure for the synthesis of **10a**, **9d** (90 mg, 0.18 mmol) was

converted to the title compound **10d** (70 mg, 84%) as a colourless oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1686

(C=O); ¹H-NMR (500 MHz, CDCl₃) ¹H-NMR (CDCl₃) δ : 0.71–0.77 (m, 6H), 1.40 (t, $J = 7.2$ Hz,

3H), 1.56 (s, 9H), 1.68–1.75 (m, 1H), 3.76 (d, $J = 5.2$ Hz, 1H), 3.82 (d, $J = 12.0$ Hz, 1H), 4.25 (d, $J =$


12.0 Hz, 1H), 4.39 (q, $J = 7.2$ Hz, 2H), 7.24–7.31 (m, 3H), 7.41–7.42 (m, 2H), 7.80 (d, $J = 8.6$ Hz,

1H), 7.88 (d, $J = 8.6$ Hz, 1H), 8.14 (s, 1H), 8.63 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.4, 17.7,

18.2, 28.5 (3C), 33.1, 60.7, 63.4, 70.1, 81.2, 114.3, 119.3, 120.5, 120.9, 123.1, 124.6, 127.5, 128.1

(2C), 130.2 (2C), 134.2, 136.8, 139.4, 153.9, 167.9; HRMS (FAB⁺) calcd for C₂₇H₃₄N₃O₄ [M+H]⁺:

464.2549, found: 464.2551.



6-Ethyl 1-methyl 2-(4-methoxybenzyl)-3-propyl-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-

dicarboxylate (10e). By use of the procedure for the synthesis of **10a**, **9e** (80 mg, 0.17 mmol) was

converted to the title compound **10e** (65 mg, 86%) as a colourless oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1701

(C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 0.71 (t, $J = 7.2$ Hz, 3H), 1.14–1.22 (m, 2H), 1.41 (t, $J = 7.2$


Hz, 3H), 1.46–1.58 (m, 2H), 3.79 (s, 3H), 3.85 (d, $J = 12.0$ Hz, 1H), 3.89 (s, 3H), 4.05 (t, $J = 6.3$ Hz,

1H), 4.24 (d, $J = 12.0$ Hz, 1H), 4.39 (q, $J = 7.2$ Hz, 2H), 6.84 (d, $J = 8.6$ Hz, 2H), 7.33 (d, $J = 8.6$ Hz,



2H), 7.81–7.87 (m, 2H), 8.11 (s, 1H), 8.51 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 13.7, 14.4, 18.4,

37.6, 53.1, 55.2, 60.8, 61.9, 64.0, 113.6 (2C), 114.3, 119.0, 120.1, 121.2, 123.1, 123.4, 128.4, 131.1

(2C), 135.6, 139.4, 154.4, 159.2, 167.7; HRMS (FAB⁺) calcd for C₂₅H₃₀N₃O₅ [M+H]⁺: 452.2186, found: 452.2177.



6-Ethyl 1-methyl 3-benzyl-2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (10f). By use of the procedure for the synthesis of **10a**, **9f** (48 mg, 0.09 mmol) was converted to the title compound **10f** (33 mg, 73%) as a light yellow oil: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1705 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.40 (t, $J = 7.2$ Hz, 3H), 2.75–2.80 (m, 1H), 2.86–2.89 (m, 1H), 3.81 (s, 3H), 3.86 (d, $J = 12.0$ Hz, 1H), 3.90 (s, 3H), 4.28–4.34 (m, 2H), 4.37 (q, $J = 7.2$ Hz, 2H), 6.85 (d, $J = 8.6$ Hz, 2H), 6.90–6.92 (m, 2H), 7.21–7.22 (m, 3H), 7.35 (d, $J = 8.6$ Hz, 2H), 7.50 (s, 1H), 7.80–7.85 (m, 2H), 7.95 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.4, 42.4, 53.1, 55.2, 60.7, 61.9, 65.7, 113.7 (2C), 114.2, 119.1, 119.8, 121.2, 123.4, 123.7, 126.8, 128.1, 128.4 (2C), 129.4 (2C), 131.0 (2C), 134.2, 136.9, 139.1, 154.4, 159.2, 167.5; HRMS (FAB⁺) calcd for C₂₉H₃₀N₃O₅ [M+H]⁺: 500.2186, found: 500.2185.




6-Ethyl 1-methyl 2-(4-methoxybenzyl)-3-phenyl-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (10g) and 6-ethyl 1-methyl 3-phenyl-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11b). By use of the procedure for the synthesis of **10a**, **9g** (50 mg, 0.097 mmol) was converted to the compound **10g** (32 mg, 68%) as a yellow oil, together with the compound **11b** (12 mg, 27%) as colourless crystals.


10g: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1697 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.23 (t, $J = 7.2$ Hz, 3H), 3.62 (s, 3H), 3.70 (s, 3H), 3.90 (d, $J = 12.0$ Hz, 1H), 4.16–4.22 (m, 2H), 4.26 (d, $J = 12.0$ Hz, 1H), 4.99 (s,

1H), 6.67 (d, $J = 8.6$ Hz, 2H), 6.79–6.81 (m, 2H), 6.99–7.01 (m, 3H), 7.19 (d, $J = 8.6$ Hz, 2H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.77 (d, $J = 8.0$ Hz, 1H), 7.94 (s, 1H), 8.90 (s, 1H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 14.3, 53.2, 55.1, 60.8, 65.8, 66.7, 113.7 (2C), 114.6, 119.2, 119.8, 121.1, 123.4, 123.6, 126.7 (2C), 127.9, 128.1, 128.7 (2C), 131.2 (2C), 134.1, 139.2, 139.7, 154.4, 159.2, 167.8; HRMS (FAB⁺) calcd for $\text{C}_{28}\text{H}_{28}\text{N}_3\text{O}_5$ [$M+\text{H}$]⁺: 486.2029, found: 486.2026.


11b: mp 229 °C; IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1737 (C=O), 1695 (C=O); ^1H -NMR (500 MHz, CDCl_3) δ : 1.43 (t, $J = 7.2$ Hz, 3H), 4.21 (s, 3H), 4.43 (q, $J = 7.2$ Hz, 2H), 7.42–7.45 (m, 1H), 7.49–7.52 (m, 2H), 7.94–7.98 (m, 3H), 8.25 (s, 1H), 8.31–8.35 (m, 2H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 14.4, 54.8, 61.1, 114.7, 117.6, 121.5, 121.6, 127.0 (2C), 127.8, 129.1 (2C), 129.5, 131.2, 131.7, 133.5, 139.9, 143.3, 150.7, 167.0; HRMS (FAB⁺) calcd for $\text{C}_{20}\text{H}_{18}\text{N}_3\text{O}_4$ [$M+\text{H}$]⁺: 364.1297, found: 364.1301.




6-Ethyl 1-methyl 2-(4-methoxybenzyl)-3-(4-nitrophenyl)-1,2,3,4-tetrahydropyrazolo[4,3-b]indole-1,6-dicarboxylate (10h). By use of the procedure for the synthesis of **10a**, **9h** (38 mg, 0.068 mmol) was converted to the title compound **10h** (26 mg, 72%) as yellow needles: mp 167 °C; IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1689 (C=O), 1514, 1347 (NO_2); ^1H -NMR (500 MHz, CDCl_3) δ : 1.40 (t, $J = 7.1$ Hz, 3H), 3.79 (s, 3H), 3.91 (s, 3H), 4.06 (d, $J = 12.6$ Hz, 1H), 4.37 (q, $J = 7.1$ Hz, 2H), 4.49 (d, $J = 12.6$ Hz, 1H), 5.23 (s, 1H), 6.84 (d, $J = 8.6$ Hz, 2H), 7.13 (d, $J = 9.2$ Hz, 2H), 7.35 (d, $J = 8.6$ Hz, 2H), 7.84 (d, $J = 8.6$ Hz, 1H), 7.90 (d, $J = 8.6$ Hz, 1H), 7.98 (d, $J = 9.2$ Hz, 2H), 8.08 (s, 1H), 8.70 (s, 1H); ^{13}C -NMR (125 MHz, CDCl_3) δ : 14.4, 53.4, 55.3, 61.0, 62.4, 65.8, 113.9 (2C), 114.6, 119.6, 119.8, 121.5, 123.9 (2C), 124.2, 124.4, 127.5 (2C), 127.6, 131.1 (2C), 131.8, 139.9, 146.3, 147.4, 154.3, 159.5, 167.6; HRMS (FAB⁺) calcd for $\text{C}_{28}\text{H}_{27}\text{N}_4\text{O}_7$ [$M+\text{H}$]⁺: 531.1880, found: 531.1873.




6-Ethyl 1-methyl 3-(4-methoxyphenyl)-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11c). By use of the procedure for the synthesis of **10a**, **9i** (38 mg, 0.07 mmol) was converted to the title compound **11c** (13 mg, 48%) as a white solid: mp 221 °C; IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1696 (C=O); $^1\text{H-NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ : 1.36 (t, $J = 7.0$ Hz, 3H), 3.85 (s, 3H), 4.12 (s, 3H), 4.34 (q, $J = 7.0$ Hz, 2H), 7.13 (d, $J = 8.0$ Hz, 2H), 7.75 (d, $J = 8.0$ Hz, 1H), 8.01 (d, $J = 8.0$ Hz, 2H), 8.14–8.18 (m, 2H), 12.04 (s, 1H); $^{13}\text{C-NMR}$ (125 MHz, $\text{DMSO-}d_6$) δ : 14.2, 54.6, 55.2, 60.6, 114.4, 114.5 (2C), 115.6, 119.6, 120.5, 122.9, 125.8, 127.9 (2C), 131.1, 131.3, 138.6, 142.9, 149.9, 160.2, 166.0; HRMS (FAB^+) calcd for $\text{C}_{21}\text{H}_{20}\text{N}_3\text{O}_5$ [$M+\text{H}$] $^+$: 394.1403, found: 394.1400.



6'-Ethyl 1'-methyl 2'-(4-methoxybenzyl)-1',2',3',4'-tetrahydrospiro[cyclohexane-1,3'-pyrazolo[4,3-*b*]indole]-1',6'-dicarboxylate (10i). Under argon atmosphere, a solution of **9j** (50 mg, 0.1 mmol) in *o*-dichlorobenzene (1 mL) was stirred at 150 °C for 2 h. After being cooled to room temperature, the resulting mixture was chromatographed on silica gel (hexane/EtOAc = 3/1) to afford the title compound **10i** (29 mg, 62%) as a yellow oil: IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1704 (C=O); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ : 1.41 (t, $J = 7.2$ Hz, 3H), 1.46–1.62 (m, 4H), 1.85–1.89 (m, 4H), 1.95–2.01 (m, 2H), 3.52 (br s, 3H), 3.79 (s, 3H), 3.88 (s, 2H), 4.41 (q, $J = 7.2$ Hz, 2H), 6.84 (d, $J = 8.0$ Hz, 2H), 7.29 (d, $J = 8.0$ Hz, 2H), 7.81–7.85 (m, 2H), 8.20 (s, 1H), 8.82 (s, 1H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ : 14.4, 23.7 (2C), 25.2, 34.1 (2C), 52.8, 55.1, 55.2, 60.7, 70.4, 113.2 (2C), 114.6, 118.8, 120.9, 121.4, 123.1, 123.2, 129.7, 131.3 (2C), 138.7, 141.8, 155.4, 158.8, 167.8; HRMS (FAB^+) calcd for $\text{C}_{27}\text{H}_{32}\text{N}_3\text{O}_5$ [$M+\text{H}$] $^+$: 478.2342, found: 478.2350.




6-Ethyl 1-methyl 4-benzyl-2-(4-methoxybenzyl)-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (15a). By use of the procedure for the synthesis of **15c**, **10j** (50 mg, 0.12 mmol) was converted to the title compound **15a** (43 mg, 71%) as a yellow oil: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1700 (C=O); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ : 1.41 (t, $J = 7.2$ Hz, 3H), 3.78 (s, 3H), 3.87 (s, 3H), 3.93 (br s, 2H), 3.97 (br s, 2H), 4.39 (q, $J = 7.2$ Hz, 2H), 5.23 (s, 2H), 6.80 (d, $J = 8.6$ Hz, 2H), 7.03–7.05 (m, 2H), 7.18 (d, $J = 8.6$ Hz, 2H), 7.30–7.32 (m, 3H), 7.83–7.88 (m, 2H), 8.09 (s, 1H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ : 14.4, 48.7, 51.7, 53.1, 55.2, 60.8, 62.3, 112.3, 113.6 (2C), 119.1, 119.6, 121.1, 122.6, 123.4, 127.1 (2C), 127.8, 128.2, 129.0 (2C), 131.0 (2C), 133.9, 136.1, 139.7, 154.4, 159.2, 167.5; HRMS (FAB⁺) calcd for $\text{C}_{29}\text{H}_{30}\text{N}_3\text{O}_5$ [$M+\text{H}$]⁺: 500.2186, found: 500.2181.




6-Ethyl 1-methyl 2-(4-methoxybenzyl)-4-(4-nitrophenyl)-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (15b). By use of the procedure for the synthesis of **15c**, **10j** (50 mg, 0.12 mmol) was converted to the title compound **15b** (45 mg, 70%) as a yellow oil. In this case, 1-fluoro-4-nitrobenzene (16 μL , 0.15 mmol) was used: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1705 (C=O), 1513, 1343 (NO_2); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ : 1.41 (t, $J = 7.1$ Hz, 3H), 3.77 (s, 3H), 3.91 (s, 3H), 4.13 (s, 2H), 4.34 (br s, 2H), 4.40 (q, $J = 7.1$ Hz, 2H), 6.83 (d, $J = 8.6$ Hz, 2H), 7.32 (d, $J = 8.6$ Hz, 2H), 7.50 (d, $J = 8.6$ Hz, 2H), 7.93–7.98 (m, 2H), 8.22 (s, 1H), 8.40 (d, $J = 8.6$ Hz, 2H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ : 14.4, 52.7, 53.3, 55.3, 61.1, 62.8, 113.2, 113.7 (2C), 120.1, 121.4 (2C), 123.0, 123.6, 125.4 (2C),

125.9, 126.4, 127.6, 130.8 (2C), 132.1, 139.0, 142.7, 145.6, 154.5, 159.4, 166.9; HRMS (FAB⁺)
calcd for C₂₈H₂₇N₄O₇ [M+H]⁺: 531.1880, found: 531.1884.




6-Ethyl 1-methyl 4-benzyl-2-(4-methoxybenzyl)-3-phenyl-1,2,3,4-tetrahydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (15d). By use of the procedure for the synthesis of **15c**, **10g** (60 mg, 0.12 mmol) was converted to the title compound **15d** (58 mg, 82%) as a yellow oil: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1703 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.40 (t, *J* = 7.2 Hz, 3H), 3.79 (s, 3H), 3.88 (s, 3H), 3.90 (d, *J* = 12.0 Hz, 1H), 4.31 (d, *J* = 12.0 Hz, 1H), 4.36–4.41 (m, 2H), 4.72 (d, *J* = 15.5 Hz, 1H), 4.75 (s, 1H), 5.30 (d, *J* = 15.5 Hz, 1H), 6.69–6.70 (m, 2H), 6.78 (d, *J* = 8.6 Hz, 2H), 6.84–6.85 (m, 2H), 7.13–7.18 (m, 5H), 7.22–7.27 (m, 3H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.99 (d, *J* = 8.0 Hz, 1H), 8.06 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.5, 48.2, 53.3, 55.1, 60.8, 62.2, 66.3, 112.6, 113.8 (2C), 119.4, 121.0, 123.1, 123.8, 126.8, 127.1 (2C), 127.3, 127.8 (2C), 128.1, 128.6 (2C), 129.0 (2C), 131.2 (2C), 131.5, 135.7, 136.3, 138.9, 140.0, 154.2, 159.2, 167.4; HRMS (FAB⁺) calcd for C₃₅H₃₄N₃O₅ [M+H]⁺: 576.2498, found: 576.2504.




6-Ethyl 1-methyl 1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11d). By use of the procedure for the synthesis of **11a**, **10j** (60 mg, 0.15 mmol) was converted to the title compound **11d** (48 mg, 95%) as a white solid: mp 215 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1749 (C=O), 1708 (C=O); ¹H-NMR (500 MHz, DMSO-*d*₆) δ : 1.35 (t, *J* = 7.2 Hz, 3H), 4.11 (s, 3H), 4.34 (q, *J* = 7.2 Hz, 2H), 7.74 (d, *J* = 8.6 Hz, 1H), 8.13–8.17 (m, 3H), 11.52 (s, 1H); ¹³C-NMR (125 MHz, DMSO-*d*₆) δ : 14.2, 54.7, 60.7,


114.7, 115.5, 119.5, 120.4, 125.7, 128.9, 129.9, 134.2, 142.5, 149.9, 166.1; HRMS (FAB⁺) calcd for C₁₄H₁₄N₃O₄ [M+H]⁺: 288.0984, found: 288.0987.



6-Ethyl 1-methyl 3-isopropyl-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11e). By use of the procedure for the synthesis of **11a**, **10b** (49 mg, 0.11 mmol) was converted to the title compound **11e** (25 mg, 70%) as a white solid: mp 201 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1737 (C=O), 1685 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.44 (t, $J = 7.2$ Hz, 3H), 1.48 (d, $J = 6.9$ Hz, 6H), 3.29–3.38 (m, 1H), 4.17 (s, 3H), 4.45 (q, $J = 7.2$ Hz, 2H), 7.91–7.93 (m, 1H), 8.30–8.33 (m, 2H), 8.99 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 21.5 (2C), 27.9, 54.6, 61.2, 114.7, 117.1, 120.8, 121.2, 126.8, 131.8, 132.3, 142.8, 147.6, 150.6, 167.5; HRMS (FAB⁺) calcd for C₁₇H₂₀N₃O₄ [M+H]⁺: 330.1454, found: 330.1451.




6-Ethyl 1-methyl 4-benzyl-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11f). By use of the procedure for the synthesis of **11a**, **15a** (40 mg, 0.08 mmol) was converted to the title compound **11f** (28 mg, 93%) as a white solid: mp 142 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1735 (C=O), 1703 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.43 (t, $J = 7.2$ Hz, 3H), 4.18 (s, 3H), 4.43 (q, $J = 7.2$ Hz, 2H), 5.41 (s, 2H), 7.20–7.22 (m, 2H), 7.31–7.34 (m, 4H), 7.92–7.94 (m, 1H), 8.20 (s, 1H), 8.32–8.33 (m, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.4, 49.0, 54.8, 61.1, 112.4, 113.8, 116.4, 120.6, 121.4, 127.1, 127.4, 127.5 (2C), 128.3, 129.0 (2C), 135.5, 135.6, 143.1, 150.3, 166.9; HRMS (FAB⁺) calcd for C₂₁H₂₀N₃O₄ [M+H]⁺: 378.1454, found: 378.1449.




6-Ethyl 1-methyl 4-(4-nitrophenyl)-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11g).

By use of the procedure for the synthesis of **11a**, **15b** (120 mg, 0.23 mmol) was converted to the title compound **11g** (80 mg, 87%) as a yellow solid: mp 228 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1754 (C=O), 1731 (C=O), 1523, 1348 (NO₂); ¹H-NMR (500 MHz, CDCl₃) δ : 1.43 (t, J = 6.9 Hz, 3H), 4.23 (s, 3H), 4.44 (q, J = 6.9 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.90 (s, 1H), 8.03 (d, J = 8.6 Hz, 1H), 8.41 (s, 1H), 8.43 (d, J = 8.6 Hz, 1H), 8.48 (d, J = 8.0 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.4, 55.1, 61.4, 113.4, 118.5, 122.3, 123.0, 123.4 (2C), 126.0 (2C), 127.2, 128.8, 133.0, 134.6, 142.1, 143.4, 145.8, 150.2, 166.4; HRMS (FAB⁺) calcd for C₂₀H₁₇N₄O₆ [$M+H$]⁺: 409.1148, found: 409.1148.




6-Ethyl 1-methyl 4-benzyl-3-isopropyl-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11h).

By use of the procedure for the synthesis of **11a**, **15c** (60 mg, 0.11 mmol) was converted to the title compound **11h** (39 mg, 84%) as a yellow oil: IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1740 (C=O), 1709 (C=O); ¹H-NMR (500 MHz, CDCl₃) δ : 1.31 (d, J = 6.9 Hz, 6H), 1.40 (t, J = 7.2 Hz, 3H), 3.10–3.18 (m, 1H), 4.18 (s, 3H), 4.39 (q, J = 7.2 Hz, 2H), 5.58 (s, 2H), 6.97–6.99 (m, 2H), 7.24–7.29 (m, 3H), 7.90–7.92 (m, 1H), 8.09 (s, 1H), 8.36 (br s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ : 14.3, 21.8 (2C), 27.6, 48.2, 54.7, 61.0, 112.5, 116.6, 120.7, 121.5, 125.7 (2C), 127.0, 127.8, 128.9 (2C), 131.4, 133.4, 136.9, 143.3, 147.3, 150.5, 167.0; HRMS (FAB⁺) calcd for C₂₄H₂₆N₃O₄ [$M+H$]⁺: 420.1923, found: 420.1921.




6-Ethyl 1-methyl 4-benzyl-3-phenyl-1,4-dihydropyrazolo[4,3-*b*]indole-1,6-dicarboxylate (11i).


By use of the procedure for the synthesis of **11a**, **15d** (50 mg, 0.09 mmol) was converted to the title compound **11i** (27 mg, 69%) as a white solid: mp 185 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1742 (C=O), 1710 (C=O); $^1\text{H-NMR}$ (500 MHz, CDCl_3) δ : 1.41 (t, $J = 7.2$ Hz, 3H), 4.21 (s, 3H), 4.40 (q, $J = 7.2$ Hz, 2H), 5.46 (s, 2H), 6.84–6.90 (m, 2H), 7.18–7.23 (m, 3H), 7.36–7.42 (m, 3H), 7.57–7.58 (m, 2H), 7.95 (d, $J = 8.0$ Hz, 1H), 8.11 (s, 1H), 8.41–8.42 (m, 1H); $^{13}\text{C-NMR}$ (125 MHz, CDCl_3) δ : 14.5, 48.1, 54.8, 61.1, 113.0, 116.6, 120.8, 121.7, 126.2 (2C), 127.4, 127.9, 128.5, 128.6 (2C), 128.8 (2C), 129.0 (2C), 129.4, 130.9, 133.2, 136.6, 141.1, 143.8, 150.6, 166.9; HRMS (FAB⁺) calcd for $\text{C}_{27}\text{H}_{24}\text{N}_3\text{O}_4$ [$M+\text{H}$]⁺: 454.1767, found: 454.1761.




3-Isopropyl-1,4-dihydropyrazolo[4,3-*b*]indole-6-carboxylic acid (5b). By use of the procedure for the synthesis of **5a**, **11e** (43 mg, 0.13 mmol) was converted to the title compound **5b** (26 mg, 82%) as a white solid: mp >300 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1663 (C=O); $^1\text{H-NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ : 1.37 (d, $J = 6.9$ Hz, 6H), 3.14–3.20 (m, 1H), 7.63 (d, $J = 8.4$ Hz, 1H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.98 (s, 1H), 10.67 (s, 1H), 12.55–12.64 (m, 2H); $^{13}\text{C-NMR}$ (125 MHz, $\text{DMSO-}d_6$) δ : 22.3 (2C), 26.4, 113.6, 114.6, 117.1, 119.7, 128.6, 135.7, 144.6, 147.4, 168.4, 171.2; HRMS (FAB⁺) calcd for $\text{C}_{13}\text{H}_{14}\text{N}_3\text{O}_2$ [$M+\text{H}$]⁺: 244.1086, found: 244.1094; t_{R} (method A): 22.64 min.




3-Phenyl-1,4-dihydropyrazolo[4,3-*b*]indole-6-carboxylic acid (5c). By use of the procedure for the synthesis of **5a**, **11b** (12 mg, 0.03 mmol) was converted to the title compound **5c** (8 mg, 87%) as a light yellow solid. In this case, compound **5c** precipitated after the neutralization, which was collected by filtration: mp >300 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1688 (C=O); $^1\text{H-NMR}$ (500 MHz, DMSO- d_6) δ : 7.31–7.34 (m, 1H), 7.49–7.52 (m, 2H), 7.71 (d, $J = 7.6$ Hz, 1H), 7.84 (d, $J = 7.6$ Hz, 1H), 7.95–7.99 (m, 2H), 8.06 (s, 1H), 11.27 (s, 1H), 12.81–13.22 (m, 2H); $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ : 113.9, 118.5, 119.5, 124.7, 124.9 (2C), 126.3, 126.7, 127.0, 128.8, 129.0 (2C), 129.5, 131.9, 144.3, 167.9; HRMS (FAB $^+$) calcd for $\text{C}_{16}\text{H}_{12}\text{N}_3\text{O}_2$ [$M+\text{H}$] $^+$: 278.0929, found: 278.0935; t_{R} (method B): 13.07 min.




4-Benzyl-1,4-dihydropyrazolo[4,3-*b*]indole-6-carboxylic acid (5d). By use of the procedure for the synthesis of **5a**, **11f** (40 mg, 0.11 mmol) was converted to the title compound **5d** (25 mg, 81%) as a white solid: mp >300 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1683 (C=O); $^1\text{H-NMR}$ (500 MHz, DMSO- d_6) δ : 5.47 (s, 2H), 7.22–7.31 (m, 5H), 7.54 (s, 1H), 7.71 (d, $J = 8.4$ Hz, 1H), 7.86 (d, $J = 8.4$ Hz, 1H), 8.11 (s, 1H), 12.79–13.09 (m, 2H); $^{13}\text{C-NMR}$ (125 MHz, DMSO- d_6) δ : 48.1, 111.8, 114.2, 117.4, 118.9, 119.4, 126.3, 127.2 (2C), 127.4, 128.6 (2C), 134.3, 135.9, 137.5, 143.8, 167.9; HRMS (FAB $^+$) calcd for $\text{C}_{17}\text{H}_{14}\text{N}_3\text{O}_2$ [$M+\text{H}$] $^+$: 292.1086, found: 292.1085; t_{R} (method B): 13.08 min.



4-(4-Nitrophenyl)-1,4-dihydropyrazolo[4,3-*b*]indole-6-carboxylic acid (5e). By use of the procedure for the synthesis of **5a**, **11g** (37 mg, 0.09 mmol) was converted to the title compound **5e** (23 mg, 79%) as a yellow solid. In this case, compound **5e** precipitated after the neutralization, which was collected by filtration: mp >300 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1683 (C=O), 1503, 1308 (NO₂); ¹H-NMR (500 MHz, DMSO-*d*₆) δ : 7.92 (d, *J* = 7.6 Hz, 1H), 7.98–8.03 (m, 3H), 8.09 (s, 1H), 8.42 (s, 1H), 8.46 (d, *J* = 8.4 Hz, 2H), 12.76–13.83 (m, 2H); ¹³C-NMR (125 MHz, DMSO-*d*₆) δ : 113.1, 119.7, 120.8, 121.4 (2C), 122.6, 125.6, 125.9 (2C), 127.8, 131.6, 138.8, 142.0, 143.3, 144.5, 167.4; HRMS (FAB⁺) calcd for C₁₆H₁₁N₄O₄ [*M*+H]⁺: 323.0780, found: 323.0774; *t*_R (method B): 17.46 min.





4-Benzyl-3-isopropyl-1,4-dihydropyrazolo[4,3-*b*]indole-6-carboxylic acid (5f). By use of the procedure for the synthesis of **5a**, **11h** (35 mg, 0.08 mmol) was converted to the title compound **5f** (20 mg, 72%) as a white solid: mp >300 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1682 (C=O); ¹H-NMR (500 MHz, DMSO-*d*₆) δ : 1.15 (d, *J* = 6.9 Hz, 6H), 3.13–3.19 (m, 1H), 5.58 (s, 2H), 6.98–6.99 (m, 2H), 7.19–7.22 (m, 1H), 7.25–7.28 (m, 2H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 1H), 8.02 (s, 1H), 12.69–12.85 (m, 2H); ¹³C-NMR (125 MHz, DMSO-*d*₆) δ : 22.9 (2C), 25.7, 47.4, 111.7, 117.0, 118.8, 119.4, 125.9 (2C), 126.2, 127.2, 128.6 (2C), 130.5, 134.3, 136.5, 138.4, 144.1, 167.9; HRMS (FAB⁺) calcd for C₂₀H₂₀N₃O₂ [*M*+H]⁺: 334.1555, found: 334.1559; *t*_R (method B): 18.82 min.







4-Benzyl-3-phenyl-1,4-dihydropyrazolo[4,3-*b*]indole-6-carboxylic acid (5g). By use of the procedure for the synthesis of **5a**, **11i** (25 mg, 0.06 mmol) was converted to the title compound **5g** (18 mg, 89%) as a white solid: mp >300 °C; IR (neat): $\nu_{\max}/\text{cm}^{-1}$ 1687 (C=O); $^1\text{H-NMR}$ (500 MHz, $\text{DMSO-}d_6$) δ : 5.57 (s, 2H), 6.88–6.90 (m, 2H), 7.16–7.20 (m, 3H), 7.35–7.45 (m, 3H), 7.60–7.62 (m, 2H), 7.77 (d, $J = 7.6$ Hz, 1H), 7.93 (d, $J = 7.6$ Hz, 1H), 8.09 (s, 1H), 12.79–13.42 (m, 2H); $^{13}\text{C-NMR}$ (125 MHz, $\text{DMSO-}d_6$) δ : 47.6, 112.2, 117.2, 119.1, 120.0, 125.9 (2C), 126.2 (2C), 126.8, 127.0, 127.5, 127.9 (2C), 128.4, 128.6, 128.8 (2C), 130.8, 131.5, 137.7, 144.5, 167.8; HRMS (FAB⁺) calcd for $\text{C}_{23}\text{H}_{18}\text{N}_3\text{O}_2$ [$M+\text{H}$]⁺: 368.1399, found: 368.1409; t_{R} (method B): 15.32 min.



References



1. C.-I. Lin, S. Selvi, J.-M. Fang, P.-T. Chou., C.-H. Lai and Y.-M. Cheng, *J. Org. Chem.*, 2007, **72**, 3537–3542.
2. A. Varela-Fernández, J. A. Varela and C. Saá, *Adv. Synth. Catal.*, 2011, **353**, 1933–1937.
3. N. Sakai, K. Tamura, K. Shimamura, R. Ikeda and T. Konakahara, *Org. Lett.*, 2012, **14**, 326–329.
4. F. Roschangar, J. Liu, E. Estanove, M. Dufour, S. Rodríguez, V. Farina, E. Hickey, A. Hossain, P. Jones, H. Lee, B. Z. Lu, R. Varsolona, J. Schröder, P. Beaulieu, J. Gillard and C. H. Senanayake, *Tetrahedron Lett.*, 2008, **49**, 363–366.



























































D:\FILE E19-H CDCL3-1.als
 COMMENT single_pulse
 DATIM 2012-09-13 09:57:50
 OEMUC 1M
 EXMOD single_pulse.ex2
 OFFRQ 500.16 MHz
 OSEET 2.41 KHz
 OFFIN 6.01 Hz
 POINT 13107
 FEQU 7507.39 Hz
 SCANS 8
 ACQTH 1.7459 sec
 PD 5.0000 sec
 PUL 6.50 usec
 IEMUC 1M
 CTMP 25.6 c
 SLUNT CDCL3
 EXREP 0.00 ppm
 BF 0.12 Hz
 RGAIN 46







D:\FILE E19-C CDCL3-1.als
 COMMENT single_pulse decoupled gat
 DATIM 2012-09-13 10:43:59
 OEMUC 13C
 EXMOD single_pulse_dec
 OFFRQ 125.77 MHz
 OSEET 7.87 KHz
 OFFIN 4.21 Hz
 POINT 26214
 FEQU 31446.06 Hz
 SCANS 948
 ACQTH 0.8226 sec
 PD 2.0000 sec
 PUL 11.20 usec
 IEMUC 1M
 CTMP 25.9 c
 SLUNT CDCL3
 EXREP 77.00 ppm
 BF 0.12 Hz
 RGAIN 54


























































C:\Documents and Settings\hogenius\My Documents\NMR data\03\0170 Proton-1-1.als




D170_Proton-1-1.als
 single_pulse
 2013-01-09 10:28:15
 1M
 proton.gcp
 399.78 MHz
 4.19 KHz
 7.29 Hz
 13107
 6002.40 Hz
 8
 2.1827 sec
 5.0000 sec
 4.65 usec
 1M
 26.1 c
 CDCl3
 0.00 ppm
 0.12 Hz
 40







C:\Documents and Settings\hogenius\My Documents\NMR data\03\0170 Carbon-1-1.als




D170_Carbon-1-1.als
 single_pulse decoupled gat
 2013-01-09 10:30:07
 13C
 carbon.gcp
 100.62 MHz
 5.25 KHz
 5.86 Hz
 26214
 25125.60 Hz
 400
 1.0423 sec
 2.0000 sec
 3.00 usec
 1M
 26.3 c
 CDCl3
 77.00 ppm
 0.12 Hz
 60









C:\Documents and Settings\hogenius\My Documents\NMR data\03\ES2-H DMSO-1.a1s



D:\FILE ES2-H DMSO-1.a1s
 COMMENT single_pulse
 DATIM 2012-11-12 15:23:02
 OEMUC LM
 EXMOD single_pulse.ex2
 OFFRQ 500.16 MHz
 OFSET 2.41 KHz
 OFFIN 6.01 Hz
 POINT 13107
 FEQU 7507.39 Hz
 SCANS 8
 ACQTH 1.7459 sec
 PD 5.0000 sec
 PUL 6.50 usec
 IEMUC LM
 CTMP 24.5 c
 SLOTT DMSO
 EXREF 2.49 ppm
 BF 0.12 Hz
 RGAIN 46



C:\Documents and Settings\hogenius\My Documents\NMR data\03\ES2-C DMSO-1.a1s



D:\FILE ES2-C DMSO-1.a1s
 COMMENT single_pulse decoupled gat
 DATIM 2012-11-12 16:11:44
 OEMUC 13C
 EXMOD single_pulse_dec
 OFFRQ 125.77 MHz
 OFSET 7.87 KHz
 OFFIN 4.21 Hz
 POINT 26214
 FEQU 31446.06 Hz
 SCANS 959
 ACQTH 0.8226 sec
 PD 2.0000 sec
 PUL 3.73 usec
 IEMUC LM
 CTMP 24.6 c
 SLOTT DMSO
 EXREF 39.50 ppm
 BF 0.12 Hz
 RGAIN 54

